Clinical Trials
BPX-101 and CaspaCIDe™ DLI are each under evaluation in single site dose escalation Phase I/II clinical trials in Houston, TX, in combination with AP1903. A single agent dose escalation Phase I trial of AP1903 in healthy volunteers was conducted by ARIAD Pharmaceuticals.
|
|
|
AP1903 |
1711/1 |
Healthy volunteers |
ARIAD |
Covance UK |
S.D. Oliver, MB |
I |
28 |
Complete |
|
BPX-101 + AP1903 |
BP-PC-001 |
mCRPC |
Bellicum |
UTHSC-H |
Guru Sonpavde, MD |
I/II |
18 |
Closed |
|
CaspaCIDe™ DLI + AP1903 |
CASPALLO |
ALL, NHL |
Baylor College of Medicine |
BCM, TXCCC, TMH |
Malcolm Brenner, MB, PhD |
I/II |
18 |
Enrolling |
|
